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Background: Uncertainty remains about possible cardiac adaptation to resistance training. Androgenic ana-
bolic steroids (AAS) use plays a potential role and may have adverse cardiovascular effects.
Objective: To elucidate the effect of resistance training and of AAS-use on cardiac dimensions and function.
Participants: Cardiacmagnetic resonance (CMR)were performed in 156male subjects aged 18–40 years: 52 non-
athletes (maximum of 3 exercise hours/week), 52 strength–endurance (high dynamic–high static, HD–HS)
athletes and 52 strength (low dynamic–high static, LD–HS) trained athletes (athletes ≥6 exercise hours/week).
28 LD–HS athletes denied and 24 admitted to AAS use for an average duration of 5 years (range 3 months–
20 years).
Results: No signiﬁcant differences were found between non-athletes and non-AAS-using LD–HS athletes. AAS-
using LD–HS athletes had signiﬁcantly larger LV and RV volumes and LV wall mass than non-AAS-using LD–
HS athletes, but lower than HD–HS athletes. In comparison to all other groups AAS-using LD–HS athletes showed
lower ejection fractions of both ventricles (LV/RV EF 51/48% versus 55–57/51–52%) and lower E/A ratios (LV/RV
1.5/1.2 versus 1.9–2.0/1.4–1.5) as an indirect measure of diastolic function. Linear regression models demon-
strated a signiﬁcant effect of AAS-use on LV EDV, LV EDM, systolic function and mitral valve E/A ratio (all
ANOVA-tests pb0.05).
Conclusions: Strength athletes who use AAS show signiﬁcantly different cardiac dimensions and biventricular
systolic dysfunction and impaired ventricular inﬂow as compared to non-athletes and non-AAS-using strength
athletes. Increased ventricular volume and mass did not exceed that of strength–endurance athletes. These ﬁnd-
ings may help raise awareness of the consequences of AAS use.© 2012 Elsevier Ireland Ltd. All rights reserved.1. Introduction
Controversy remains over the cardiac adaptations of strength ath-
letes to resistance training. The inﬂuence of androgenic anabolic ste-
roids (AAS) use on structural cardiac adaptation is similarly unclear,
but likely to be clinically relevant, as AAS-use has been reported to
have adverse effects on ventricular function [1–5] and the cardiovas-
cular system in general [6]. The prevalence of AAS use is probably
underestimated by most physicians, and is reckoned to be over 3% [6].
As different sports disciplines impose different patterns of hemo-
dynamic strain upon the heart, they are likely to result in different
patterns and degrees of cardiac adaptation. A useful and well-y, room E 01.132, University
X, Utrecht, The Netherlands.
Ltd. All rights reserved.established framework for classifying sports disciplines, based upon
the degree of dynamic (endurance/isotonic) and static (resistance/
isometric) strain they exert [7], would classify typical strength train-
ing as low dynamic–high static (LD–HS).
LD–HS sports cause an increased afterload due to an elevation of
arterial blood pressure of up to 480/350 mm Hg, while cardiac output
remains virtually the same [8]. Under these conditions an adaptive
pattern of concentric hypertrophy with selective ventricular wall
thickening and without substantial changes in ventricular volume
has been postulated and is known as the ‘Morganroth hypothesis’
[9]. Additionally, we assume that the upper limits of cardiac adapta-
tion in strength athletes will fall within those of high dynamic–high
static (HD–HS) athletes [9,10].
Existing studies on LD–HS athletes have come to contradictory
conclusions, varying between reports of absence of ventricular
changes [11–13], moderate changes [14–16] and greater adaptations
that are similar to those observed inHD–HS athletes [17]. A complicating
Table 1
Baseline characteristics.
Non-
athletes
Non-using
LD–HS athletes
AAS-using
LD–HS athletes
HD–HS
athletes
p-
Value
n 52 28 24 52
Age (years) 28±5.8 27±6.5 29±4.6 28±5.6 NS
Height (m) 184±7.1 180±7.4 183±7.8 185±7.0 NS
weight (kg) 79±9.4 94±17 107±17 77±9.6 b0.01
BSA (m2) 2.02±0.14 2.13±0.21 2.28±0.20 2.00±0.15 b0.01
SBP (mm Hg) 128±11 131±13 136±12 127±10 NS
DBP (mm Hg) 76±8.9 72±9.4 76±7.3 73±9.2 NS
Weekly training
(hours)
1.5±1.3 11±5.6 11±4.6 18±7.4 b0.01
Data are expressed as mean±SD, AAS = anabolic androgenic steroids, HD–HS = high
dynamic–high static, BSA = body surface area, SBP/DBP = systolic/diastolic blood
pressure, NS = non-signiﬁcant at signiﬁcance level of 0.05.
665T. Luijkx et al. / International Journal of Cardiology 167 (2013) 664–668factor in the assessment of physiologic cardiac adaptation in strength
athletes is the frequent use of AAS, as AAS-use results in generalized
muscular hypertrophy.
2. Objectives
To investigate the effects of strength training on cardiac dimen-
sions and function we compared LD–HS athletes with age and sex
matched HD–HS athletes and a control group of non-athletes. We
further hypothesized that AAS-use could inﬂuence cardiac dimen-
sions and function, so two groups of LD–HS athletes who either
admitted or denied AAS-use were compared.
3. Methods
Cardiac magnetic resonance (CMR) imaging according to a standardized protocol
on 156 male subjects aged 18 to 40 years: 52 control subjects (non-athletes) exercising
a maximum of 3 h a week, 52 HD–HS athletes (13 cycling, 17 rowing, 19 tri-/biathlon, 3
other) and 52 LD–HS athletes (16 bodybuilding, 13 powerlifting, 7 weightlifting, 5
strongman, 11 other). All athletes trained at least 6h/week (mean training 11.5 h/week
and mean training history was 7.3 years) and all competed at national or international
level.
Of the LD–HS athletes 28 denied and 24 admitted using AAS for an average dura-
tion of 5 years (range 3 months–20 years), starting at least 6 months prior to the MRI
scan. No non-athletes or HD–HS athletes admitted to using AAS or other similar
medication.
Clinical or historical evidence of hypertension or cardiovascular, pulmonary,metabolic
disease was absent in all subjects. The study was approved by the institutional ethics
committee and all subjects gave written informed consent.Table 2
Quantitative ventricular parameters adjusted for body surface area.
Non-athletes Non-usin
LD–HS at
n 52 28
LV
EDV index (ml/m2) 100±15 (127)‡§ 104±19
ESV index (ml/m2) 43±9.6 (61)‡§ 47±12
EDM index (ml/m2) 47±8.2 (63)‡§ 47±8.5
EDD SA (mm) 56±3.8 (63)‡§ 58±4.4
EF (%) 57±5.9 (47)‡ 55±4.7
MV E/A ratio 1.9±0.45 (1.2)‡ 1.9±0.4
RV
EDV index (ml/m2) 110±17 (139)§ 110±17
ESV index (ml/m2) 53±11 (72)‡§ 54±9.9
EDM index (ml/m2) 12±2.3 (15)§ 12±1.9
EDD SA (mm) 45±5.9 (56)§ 47±5.8
EF (%) 52±5.0 (43)‡ 51±4.1
TV E/A ratio 1.5±0.31 (1.0)‡ 1.4±0.3
IVS-WT SA (mm) 9.5±1.3 (12)‡§ 9.4±1.5
Data are expressed as mean±SD (95th percentile or 5th percentile where appropriate), ED
= end-diastolic diameter, SA=short axis view, EF=ejection fraction, IVS-WT = interventri
using LD–HS athletes (¶), AAS-using LD–HS athletes (‡), HD–HS athletes (§) are indicated.3.1. Image acquisition
CMR imaging was performed on a 1.5 T MRI scanner (Achieva, Philips, Best, The
Netherlands) including multi-directional steady-state free precession (SSFP) cine
imaging, and ﬂow measurements of all four cardiac valves. The scan protocol in
athletes and non-athletes has been described in detail previously [18].
3.2. Image analysis
Ventricular endo- and epicardial contours were traced on a workstation (View
Forum cardiac package version R5.1V1L2.SP3, Philips, Best, The Netherlands) by
blinded observers using a contour tracing protocol shown to be reliable and reproduc-
ible [19]. Results were checked by a blinded observer experienced in CMR before being
entered in the data ﬁle.
End-diastolic (ED) and end-systolic (ES) endocardial contours were used to calcu-
late end-diastolic (EDV) and end-systolic (ESV) volumes, stroke volumes (SV), derived
ejection fractions (EF), and ED wall mass (EDM). The right and left ventricular outﬂow
tracts (RVOT, LVOT) were included in the endocardial contours, whereas papillary
muscles and trabeculae were excluded from the endocardial border, thus becoming
part of the blood volume [19]. End-diastolic ventricular diameters and septal wall
thickness were measured on the short axis images. As an indirect measure of diastolic
function quantitative ﬂow images over the mitral and tricuspid valves were used to
calculate ratios of the early (E-peak) and late diastolic ﬁlling wave (A-peak) [20–22].
3.3. Statistical analysis
Data are presented as themean±2 standard errors. CMRvolumes andwallmasswere
indexed to body surface area (BSA), with BSA calculated as: BSA (m2)=
0.20247×height (m)0.725×weight (kg)0.425 [23]. Multivariable linear regression
models were ﬁtted in the 52 LD–HS athletes to quantify a possible relation of
AAS-use to ventricular changes given the covariates age, hours of weekly training
and AAS-use (yes/no). The sample size limited the number of possible covariates,
and these covariates were considered the most relevant for the outcome variables
in this study, based on previous research [18,24]. The models were backward
stepwise speciﬁed using the Akaike's Information Criterion [25].
4. Results
Baseline characteristics of all subject groups are shown in Table 1.
LD–HS athletes in general had a signiﬁcantly larger weight and BSA.
The slightly higher mean age and blood pressure in the AAS-using
LD–HS athletes were not statistically signiﬁcant. The difference in
training hours is accounted for by inclusion as a covariate in the linear
regression model.
Ventricular volumes, wall mass and ejection fraction, indexed to
BSA if relevant, are shown in Table 2. There was a substantially larger
LV and RV end-diastolic volume (EDV) and end-diastolic wall mass
(EDM) in HD–HS athletes as compared to non-athletes and non-
using LD–HS athletes. On the one hand, non-AAS-using LD–HS
athletes showed no differences from non-athletes in ventricularg
hletes
AAS-using
LD–HS athletes
HD–HS athletes
24 52
(138)§ 113±17 (154)†§ 126±15 (154)†¶‡
(73)‡§ 56±13 (86)†¶ 55±10 (79)†¶
(64)‡§ 59±15 (88)†¶ 65±12 (89)†¶
(66)‡ 61±3.8 (68)†¶ 60±4.1 (67)†
(44)‡ 51±6.9 (37)†¶§ 56±4.8 (45)‡
8 (1.0)‡ 1.5±0.31 (0.9)†¶§ 2.0±0.50 (1.3)‡
(136)§ 119±19 (164)§ 141±20 (184)†¶‡
(69)‡§ 62±13 (91)†¶§ 70±13 (97)†¶‡
(15)§ 11±1.4 (15)§ 14±2.4 (21)†¶‡
(57) 48±7.2 (60) 48±5.8 (59)†
(45)‡ 48±5.5 (39)†¶§ 51±4.1 (44)‡
0 (1.0)‡ 1.2±0.27 (0.9)†¶§ 1.5±0.30 (1.0)‡
(13)‡§ 12±1.8 (15)†¶ 11±1.3 (13)†¶
V=end-diastolic volume, ESV = end-systolic volume, EDM = end-diastolic mass, EDD
cular septal wall thickness, signiﬁcant differences (pb0.05) from non-athletes (†), non-
Table 3
Linear regression model coefﬁcients (change of cardiac parameter per unit change of
covariate).
Covariates Outcome variable
LV EDV (ml) LV EDM (g) LV EF (%) MV E/A ratio
AAS-use
(yes/no)
12.8 11.7 −3.83 −0.25
Age (years) −1.34 Removed
(p=0.40)
Removed
(p=0.88)
−0.04
Body surface
area (m2)
Removed
(p=0.75)
Removed
(p=0.84)
Removed
(p=0.16)
Removed
(p=0.58)
Weekly training
(hours)
Removed
(p=0.63)
Removed
(p=0.58)
Removed
(p=0.30)
Removed
(p=0.70)
LV = left ventricular, EDV = end-diastolic volume, EDM = end-diastolic mass, EF =
ejection fraction, MV = mitral valve; table gives model coefﬁcient (beta) when covar-
iate remained in the ﬁnal model (all p-valuesb0.01), otherwise p-value speciﬁed at
time of removal from the model.
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larger volumes (LV and RV) and LV wall mass than non-using
LD–HS athletes and non-athletes. Although not signiﬁcantly, the
interventricular septal wall thickness (IVS-WT) in AAS-using LD–HS
athletes was slightly larger than that of HD–HS athletes. The IVS-WT
of 36% (8 subjects) of AAS-using LD–HS athletes exceeded 12 mm in
comparison to 16% (8 subjects) of HD–HS athletes, and 4% (3 subjects)
of non-using LD–HS athletes and non-athletes combined. One subject
(AAS-using HS athlete) exceeded 15 mm with an IVS-WT of 15.5 mm
(Fig. 1).
Although the ejection fraction of both ventricles was in the same
range for HD–HS athletes, non-using LD–HS athletes and non-
athletes, it was signiﬁcantly lower in AAS-using LD–HS athletes. In
comparison to the other groups AAS-using LD–HS athletes also had
smaller E/A ratios of the tricuspid and mitral valves.
The coefﬁcients of covariates remaining in the ﬁnal linear regres-
sion model for LV EDV, EDM, EF and mitral valve E/A ratio are
shown in Table 3. AAS-use was a signiﬁcant contributor (pb0.01) to
all of these outcome variables. The linear regression coefﬁcients
quantify the (multivariable) relation between covariates and out-
come measures in our study population. AAS-use was associated
with 12.8 ml larger LV EDV and 11.7 g larger LV EDM, whereas LV
EDV was on average 1.34 ml lower with every additional year of
age. The model also suggests that AAS-use, given all covariates,
results in an LV EF that is 3.8% lower and a mitral valve E/A ratio
reduction equivalent to 6 years of aging (coefﬁcient AAS-use/age for
MV E/A ratio −0.25/−0.04). LV EDM and LV EF were not affected
by age.
5. Discussion
Selective ventricular wall thickening in strength (low dynamic–
high static) athletes is a common perception. This cross-sectional
study shows that only LD–HS athletes using AAS have a signiﬁcantly
greater wall mass and ventricular volume associated with systolicFig. 1. Comparison of AAS-using and non-AAS-using strength athletes. Cardiac MRI 4 chambe
use (A, B) with LV/RV EF of 46/43% and mitral/tricuspid valve E/A ratio of 1.3/0.9, and one d
1.8/1.5.dysfunction and altered ventricular inﬂow dynamics. Although the
larger ventricular mass and volume did not exceed that of high stat-
ic–high dynamic sports, the interventricular septal wall thickness
was slightly larger. Non-using LD–HS athletes show no signiﬁcant
differences in comparison to non-athletes, suggesting that AAS-use
may be the crucial factor in inducing the cardiac changes observed
here.
5.1. Earlier ﬁndings on LD–HS athletes
Although several echocardiographic studies supported the Mor-
ganroth hypothesis, which assumes concentric hypertrophy in LD–HS
athletes [2,15,26], other studies have reported negligible to modest
cardiac adaptation in LD–HS athletes [13,27–29], ﬁnding signiﬁ-
cantly larger ventricular wall thicknesses and/or diameters only
in sports that are high dynamic in nature [15,30].
The few CMR studies that have examined cardiac dimensions in
LD–HS athletes have also found little evidence of cardiac adaptation.r view (A, C) and short-axis view (B, D) of two strength athletes, one admitting to AAS-
enying AAS-use (C, D) with LV/RV EF of 56/52% and mitral/tricuspid valve E/A ratio of
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untrained subjects using both CMR and echocardiography and found
no differences between LD–HS athletes and untrained subjects [31].
Lalande et al. compared nine Olympic weightlifters and ten recrea-
tionally active men with CMR and reported a relative increase in fat
free mass without an increase of LV mass or wall thickness [12]. Our
results in 28 non-using LD–HS athletes support these ﬁndings.
5.2. Earlier ﬁndings on AAS-use
Although we observed negligible adaptation in non-AAS-using
LD–HS athletes, the increase in ventricular wall mass in AAS-using
LD–HS athletes came close to that of HD–HS athletes. Earlier echocar-
diographic studies observed similar ﬁndings [4,32–34].
Potentially clinically important ﬁndings here include the lower
EF as a direct measure of systolic function and lower E/A ratios as
an indirect measure of impaired diastolic function. Although E/A
ratios are not an accurate method of measuring, they do indicate
altered ventricular inﬂow dynamics. Moreover, E/A ratios, also
used by other CMR studies [35,36], are part of routine clinical prac-
tice in the assessment of diastolic function and the observed lower
E/A ratios in both ventricles in AAS-using LD–HS athletes can be
regarded as a possible sign of diastolic dysfunction. Earlier studies
have reported impaired ventricular function using echocardiogra-
phy in small samples, typically investigating 10–15 strength ath-
letes using AAS [1,4,37,38]. Moreover, Lane et al. found impaired
vascular reactivity [5] and Grace et al. proposed increased levels
of C-reactive protein as an underlying cause of peripheral arterial
disease [39].
More ominously still, several possible causes of sudden cardiac
death have been attributed to AAS in the past, and AAS has been asso-
ciated with cardiotoxicity [40], autonomic dysregulation [41], throm-
bogenic effects of increased hematocrit and homocysteine levels
[42], and arrhythmogenic factors such as a higher incidence of signal
averaged ECG abnormalities [42,43] and prolonged QTc intervals
[44]. Discontinuation of AAS-use does not seem to fully reverse all
of these effects, as illustrated by studies of the groups of Baggish et
al. [1,45] and Urhausen et al. [46]. The reported prevalence of AAS
use generally exceeds 3% in men of various ages, corresponding to
many millions and is only widespread since the 1980s and long-
term adverse effects are only recently becoming apparent [6], rein-
forcing the relevance of this study's ﬁndings.
5.3. Study limitations
Our cross-sectional study cannot assess longitudinal changes in
cardiac parameters among AAS users. Earlier studies reported persist-
ing effects of AAS even after discontinuing AAS use [33,46]. We did
not test for AAS by any means other than asking participants if they
used AAS. This reﬂects typical daily clinical practice. Whereas it is
hard to imagine non-users admitting to AAS-use, it is possible that
AAS users may not wish to admit to using AAS and were erroneously
placed in the non-using group. This would not unduly detract from
our ﬁndings as it would lead to an underestimation of the observed
differences. Heavy T2-weighted images or delayed enhancement
images, not performed in our study, could be included in future
research to assess possible edema or ﬁbrosis.
5.4. Conclusion
In conclusion, low dynamic–high static (strength) sports yield
very little cardiac adaptation, not exceeding ventricular volume and
wall mass measures of non-athletic controls, unless accompanied by
AAS-use. AAS-use is associated with larger ventricular volume and
wall mass, not exceeding that of HD–HS athletes, together with
systolic dysfunction and impaired ventricular inﬂow. The observedventricular changes in AAS-using athletes are of great clinical impor-
tance, given the widespread and often illicit use of AAS.
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